A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 23 Aug 2019
Price : $35 *
At a glance
- Drugs Pepinemab (Primary)
- Indications Neuroblastoma; Osteosarcoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 31 May 2019 Results (n=18) published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 16 Jan 2018 Status changed from not yet recruiting to recruiting.
- 28 Oct 2017 New trial record